---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-25-000060"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:43:59.780909+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira Q1 revenue $168.9M, net income $4.8M; EXPAREL exclusivity extended to 2039

## Summary
- Total revenues $168.9M (+1% YoY); GAAP net income $4.8M ($0.10) vs $9.0M ($0.19) a year ago.
- EXPAREL net sales $136.5M (+3% YoY) with 7% daily volume growth; ZILRETTA $23.3M (-10%).
- Patent litigation settled with Fresenius Kabi; limited-volume entry starts at high single-digit % of U.S. volume, exclusivity to 2039.
- Court ruling eliminates EXPAREL royalty obligation to RDF; future payments stopped, repayment sought.
- Reiterates FY2025 guidance: revenue $725-765M, non-GAAP gross margin 76-78%.

## SEC filing metadata
- accession: 0001396814-25-000060
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/0001396814-25-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000060/pcrx-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-25-000060
- JSON: https://secwatch.observer/filing/0001396814-25-000060.json
- Plain text: https://secwatch.observer/filing/0001396814-25-000060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.